Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Valeas S.p.A.
Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated:
“This agreement allows Valeas to extend its CNS portfolio adding a premium product based on natural, patented ingredient Afforn®. The product will satisfy the growing demand among the consumers looking for mood improvement medication that offers science-based and, at the same time, natural solution to their problem.
Valeas is an Italian pharmaceutical company that focuses on therapeutic areas such as asthma, chronic obstructive bronchitis, upper and lower respiratory tract infections, anxiety, insomnia, and more. The company was founded in 1934 and is based in Milan, Italy.
Pharmactive is a privately-owned Spanish company that develops, and manufactures differentiated natural ingredients supported by scientific evidence. Pharmactive makes these innovative ingredients available to other companies in the Nutraceutical and Pharmaceutical Industries for marketing and distribution.